The BRCA-P study is the first international clinical study on breast cancer prevention.
Introduction
The BRCA-P study is the first international clinical study on breast cancer prevention. It is available to women between the ages of 25 and 55 with a BRCA1 gene mutation and breast tissue that has not been surgically removed as a precaution.
Status
Recruitment was completed on 31th December 2024.
Study-Design
Originally developed for the treatment of osteoporosis, the BRCA-P study is the first to investigate whether denosumab can reduce the risk of breast cancer in women with a BRCA1 gene mutation. As part of the study, healthy women age between 25 and 55 will receive denosumab or placebo half-yearly for 5 years.
Contact
Project management
Dr. Christin Wünsche
brcap@gbg.de
+49 6102 7480-440
